WO2006016275A3 - Arn interférant spécifique vis-à-vis de la gastrine - Google Patents

Arn interférant spécifique vis-à-vis de la gastrine

Info

Publication number
WO2006016275A3
WO2006016275A3 PCT/IB2005/002686 IB2005002686W WO2006016275A3 WO 2006016275 A3 WO2006016275 A3 WO 2006016275A3 IB 2005002686 W IB2005002686 W IB 2005002686W WO 2006016275 A3 WO2006016275 A3 WO 2006016275A3
Authority
WO
WIPO (PCT)
Prior art keywords
gastrin
molecules
rnai
specific interfering
rnai molecules
Prior art date
Application number
PCT/IB2005/002686
Other languages
English (en)
Other versions
WO2006016275A2 (fr
Inventor
Susan A Watson
Anna Grabowska
Original Assignee
Aphton Corp
Susan A Watson
Anna Grabowska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aphton Corp, Susan A Watson, Anna Grabowska filed Critical Aphton Corp
Priority to EP05775595A priority Critical patent/EP1778841A2/fr
Priority to AU2005270917A priority patent/AU2005270917A1/en
Priority to CA002576576A priority patent/CA2576576A1/fr
Publication of WO2006016275A2 publication Critical patent/WO2006016275A2/fr
Publication of WO2006016275A3 publication Critical patent/WO2006016275A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/595—Gastrins; Cholecystokinins [CCK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des molécules d'acide ribonucléique interférant spécifique vis-à-vis de la gastrine (ARNi) qui exercent une régulation négative sur le gène de l'hormone gastrine. Les molécules d'ARNi de l'invention sont des molécules d'ARN double brin qui peuvent comprendre des bases modifiées et des liaisons qui ne sont pas des liaisons de type phosphate entre les bases. Les brins complémentaires des molécules d'ARNi de l'invention peuvent être liés par une chaîne de nucléotides ou par des groupes de liaison qui ne sont pas des nucléotides. Les molécules d'ARNi de l'invention peuvent être incorporées dans une formulation pharmaceutique utile dans un procédé servant à traiter des maladies ou affections médiées par la gastrine dont des tumeurs médiées par la gastrine, la maladie du reflux gastro-oesophagien (GERD), le syndrome de Zollinger-Ellison, l'hypergastrinémie, l'anémie pernicieuse, l'ulcère gastrique, l'ulcère duodénal et l'infection par H. pylori.
PCT/IB2005/002686 2004-08-11 2005-08-10 Arn interférant spécifique vis-à-vis de la gastrine WO2006016275A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05775595A EP1778841A2 (fr) 2004-08-11 2005-08-10 Arn interférant spécifique vis-à-vis de la gastrine
AU2005270917A AU2005270917A1 (en) 2004-08-11 2005-08-10 Gastrin-specific interfering RNA
CA002576576A CA2576576A1 (fr) 2004-08-11 2005-08-10 Arn interferant specifique vis-a-vis de la gastrine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60069604P 2004-08-11 2004-08-11
US60/600,696 2004-08-11

Publications (2)

Publication Number Publication Date
WO2006016275A2 WO2006016275A2 (fr) 2006-02-16
WO2006016275A3 true WO2006016275A3 (fr) 2006-05-18

Family

ID=35759261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002686 WO2006016275A2 (fr) 2004-08-11 2005-08-10 Arn interférant spécifique vis-à-vis de la gastrine

Country Status (5)

Country Link
EP (1) EP1778841A2 (fr)
KR (1) KR20070062515A (fr)
AU (1) AU2005270917A1 (fr)
CA (1) CA2576576A1 (fr)
WO (1) WO2006016275A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520010C (fr) 2003-03-28 2012-07-10 Aphton Corporation Dosages immunologiques pour la detection de l'hormone gastrine
US8889640B1 (en) * 2008-06-20 2014-11-18 Jill P. Smith Composition and method for the treatment of gastrin mediated cancers
CN111050789A (zh) 2017-06-15 2020-04-21 癌症进展有限公司 用于诱导针对肿瘤和癌症的体液免疫和细胞免疫的组合物和方法
CA3204163A1 (fr) * 2021-01-13 2022-07-21 Cancer Advances Inc. Compositions et procedes destines a la prevention de tumeurs et de cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010180A1 (fr) * 2001-07-23 2003-02-06 The Board Of Trustees Of The Leland Stanford Junior University Methodes et compositions pour l'inhibition induite par l'arni de l'expression genetique chez des mammiferes
WO2004042061A1 (fr) * 2002-11-08 2004-05-21 Klaus Strebhardt Composition pharmaceutique de suppression de l'expression non souhaitee d'un gene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010180A1 (fr) * 2001-07-23 2003-02-06 The Board Of Trustees Of The Leland Stanford Junior University Methodes et compositions pour l'inhibition induite par l'arni de l'expression genetique chez des mammiferes
WO2004042061A1 (fr) * 2002-11-08 2004-05-21 Klaus Strebhardt Composition pharmaceutique de suppression de l'expression non souhaitee d'un gene

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GRABOWSKA A ET AL: "Downregulation of the gastrin gene using small interfering RNA", REGULATORY PEPTIDES, vol. 122, no. 1, September 2004 (2004-09-01), & 15TH INTERNATIONAL SYMPOSIUM ON REGULATORY PEPTIDES; TOULOUSE, FRANCE; SEPTEMBER 19 -22, 2004, pages 46, XP009061814, ISSN: 0167-0115 *
SINGH P ET AL: "TUMORIGENICITY OF A HUMAN COLON CANCER CELL LINE IS SIGNIFICANCE REDUCED IN VIVO, IN THE PRESENCE OF COLON CANCER CELLS OVEREXPRESSING ANTISENSE GASTRIN MRNA: ROLE OF INHIBITORY (ENDOCRINE) FACTORS IN THE OBSERVED BYSTANDER EFFECTS", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, US, vol. 114, no. 4, PART 2, 15 April 1998 (1998-04-15), pages A680, XP008056925, ISSN: 0016-5085 *
SMITH J P ET AL: "Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer", CANCER LETTERS, NEW YORK, NY, US, vol. 135, no. 1, 8 January 1999 (1999-01-08), pages 107 - 112, XP002357825, ISSN: 0304-3835 *
TAKHAR A S ET AL: "The role of gastrin in colorectal carcinogenesis.", THE SURGEON : JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND. OCT 2004, vol. 2, no. 5, October 2004 (2004-10-01), pages 251 - 257, XP009061845, ISSN: 1479-666X *
WATSON S ET AL: "GASTRIN INHIBITION INCREASES THE POTENCY OF CYTOTOXIC AGENTS IN PANCREATIC CANCER", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, US, vol. 122, no. 4, SUPPL 1, April 2002 (2002-04-01), pages A241, XP008056958, ISSN: 0016-5085 *

Also Published As

Publication number Publication date
EP1778841A2 (fr) 2007-05-02
AU2005270917A8 (en) 2006-02-16
AU2005270917A1 (en) 2006-02-16
WO2006016275A2 (fr) 2006-02-16
KR20070062515A (ko) 2007-06-15
CA2576576A1 (fr) 2006-02-16

Similar Documents

Publication Publication Date Title
EP1750771A4 (fr) Micro-arn d'ilot pancreatique et methodes permettant d'inhiber ce dernier
WO2007031877A3 (fr) Modulation de proprietes immunostimulantes de petits arn interferents (petits arni) par modification de nucleotides
ATE350473T2 (de) Weitere neue formen von interferierende rns moleküle
WO2006119266A3 (fr) Micro-arn humains et procedes d'inhibition de ceux-ci
WO2004022714A3 (fr) Especes organiques facilitant le transfert de charge depuis ou vers des nanostructures
WO2006016275A3 (fr) Arn interférant spécifique vis-à-vis de la gastrine
WO2008036406A3 (fr) Compositions et procédés se rapportant à une thérapie par glissement de protéines pour la distrophie myotonique
WO2006026388A3 (fr) Techniques d'amplification d'acide nucleique avec une seule amorce
WO2009013620A3 (fr) Recombinaison homologue
WO2006032724A3 (fr) Nouvelles enzymes laccase et leurs utilisations
WO2006113198A3 (fr) Procedes permettant de faciliter l'isolation d'arn dans des echantillons biologiques
WO2006031800A3 (fr) Transfection inverse de reseaux de cellules pour des analyses structurelles et fonctionnelles de proteines
DE60234369D1 (de) Manipulierte matrizen und ihre verwendung bei der single-primer-amplifikation
WO2006066203A3 (fr) Molecules de petit arn interferent (sirna) destinees a la modulation de la superoxyde dismutase (sod)
UA94893C2 (ru) Трансгенное растение кукурузы mir604
WO2007103382A3 (fr) Éléments génétiques spécifiques d'une plante et cassettes de transfert pour la transformation de plantes
WO2008121604A3 (fr) Compositions et procédés pour inhiber l'expression d'un gène à partir du virus ébola
WO2005102326A3 (fr) Utilisation d'inhibiteurs de c-kit dans le traitement des maladies renales
WO2006029076A3 (fr) Elements genetiques propres a des plantes et cassettes de transfert pour la transformation de plantes
WO2005090572A3 (fr) Compositions et procédés servant à traiter un cancer du pancréas
WO2009027978A8 (fr) Séquences d'acides nucléiques comprenant un site de liaison nf-kb dans la région promotrice de la o(6)-méthylguanine-adn-méthyl transférase (mgmt) et leur utilisation pour le traitement du cancer et de troubles de l'immunité
IL206072A (en) A method for creating and sorting antibody library
PL1846412T3 (pl) Sposób wytwarzania 7-etylo-10-hydroksykamptotecyny
WO2009025300A1 (fr) Peptide capable de se lier à une immunoglobuline
WO2002101088A3 (fr) Capture in vitro d'acides nucleiques par l'intermediaire d'oligonucleotides modifies et de billes magnetiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2576576

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200580027254.1

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007525384

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005270917

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005775595

Country of ref document: EP

Ref document number: 1731/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020077005675

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005270917

Country of ref document: AU

Date of ref document: 20050810

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005270917

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005775595

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005775595

Country of ref document: EP